World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

ADC clinical development at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

26 organizations at World ADC San Diego 2026 present work in clinical development: 17 drug developers, 5 technology and service providers and 4 academic, government and non-profit bodies. Between them they bring 74 presentations to the program. Most represented: Daiichi Sankyo (5 on the program), Pfizer (4 on the program), AstraZeneca (4 on the program). As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–7 of 26 organizations

Organization	World ADC San Diego 2026 Attendance
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Large pharma Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.	Panel Mon Oct 12 2:30pm Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION Pre-conference: 7th Toxicity Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:30pm The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example Clinical Lessons Panel Tue Oct 13 3:30pm Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance Clinical Lessons Talk Wed Oct 14 2:00pm Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1 Preclinical Workshop Thu Oct 15 1:00pm Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company whose oncology portfolio includes ADCs gained with Seagen, such as PADCEV.	Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 11:00am PF-08046033: Advancing GPNMB Targeted Auristatin-S ADC Through Payload Modification to Improve Tolerability Preclinical Talk Tue Oct 13 12:00pm Deep-Diving Into Mechanistic Insights of a Novel ADC Payload That Inhibits Protein Translation Discovery Chemistry Talk Tue Oct 13 2:00pm Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including PADCEV – VIRTUAL PRESENTATION Clinical Lessons Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more Chair Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance Discovery Chemistry Panel Wed Oct 14 2:30pm What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation? Discovery Chemistry
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo.	Chair Unlocking the Therapeutic Power of Rationale-Driven ADC Combinations Pre-conference: 10th ADCs in Combination Day Talk Mon Oct 12 10:00am Addressing ADC Regulatory Strategy for Gross Content Testing, Linker RSM Definition & Alternative Charge Variant QC for Release & Stability Pre-conference: 8th CMC Day Talk Mon Oct 12 10:00am Combining the Past, Present & Future: Learnings, Trends & Impact of the Past 10 Years of ADC Combination Therapies Pre-conference: 10th ADCs in Combination Day Talk Tue Oct 13 11:00am Evaluating CMC Projects to Ensure Sustainable, Time & Cost Sensitive Manufacturing Across the ADC Product Portfolio Manufacturing & Supply Chain Talk Tue Oct 13 11:00am PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency Discovery Chemistry Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, Iksuda Therapeutics, Pfizer +1 more
AbbVie North Chicago, IL
abbvie.com Large pharma Global pharmaceutical company developing antibody-drug conjugates in oncology, including ABBV-400 for colorectal and other solid tumors.	Talk Mon Oct 12 2:00pm Assessing Immunogenic Senescence to Promote the Activity of Topo1 Inhibitor ADCs Pre-conference: 3rd Pharmacology Day · with MediLink Therapeutics Panel Mon Oct 12 2:30pm Breaking Down Learnings From Pharmacology & PD Profiles to Understand In-Depth Insights for the Next Wave of ADCs Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 12:00pm Exploring the Safety & Efficacy Profile of ABBV-400 in CRC to Assess ADC Impact in Unmet Solid Tumor Medical Need Clinical Lessons Talk Wed Oct 14 9:00am Delving Into Discovery of Pan-PI3K & mTOR Dual Inhibitors as a First-in-Class ADC Payload Plenary ADC discovery chemistry Talk Wed Oct 14 2:30pm Investigating Best Technologies & Methods to Scale Up Process From Lab to GMP Across ADC Formats Process & Analytical Development
Iksuda Therapeutics Newcastle upon Tyne, UK
iksuda.com Biotech UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.	Chair Tue Oct 13 7:55am Part of Striving for the Next Wave of ADC Innovation: Contextualizing Novel ADC Mechanism & Design Validation to De-Risk Future ADC Development & Deliver Differentiated Patient Benefit Chair’s Opening Remarks Plenary ADC discovery chemistryADC discovery biology Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:00pm Beyond TopoI & Tubulin: Advancing a First-in-Class Protein Alkylation Payload ADC IKS073 Preclinical Talk Tue Oct 13 3:00pm Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing Clinical Lessons Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Pfizer +1 more Chair Navigating New & Crowded ADC Clinical Indications to Achieve Differentiation & Maximize Benefit to Patients Clinical Lessons Panel Wed Oct 14 12:30pm Navigating & Maximizing ADC Clinical Development to Best Deliver Patient Impact in Crowded Oncology Indications Clinical Lessons Panel Wed Oct 14 3:00pm Exploring Opportunities to Achieve Differentiated Clinical Benefit in a Crowded ADC Landscape Clinical Lessons Chair Wed Oct 14 5:30pm Part of Delving Into ADC Performance in Crowded Clinical Indications With Approved ADC Therapies to Understand How Differences in Biconjugate Design & Clinical Strategy Correlates to Patient Impact Chair’s Closing Remarks Plenary Clinical development Workshop Thu Oct 15 9:00am Connecting ADC Design & Component Contribution to Clinical Safety & Efficacy: What Makes a Clinically Impactful ADC? Post-conference workshop for Translational Medicine & Clinical Lessons
Sutro Biopharma South San Francisco, CA
sutrobio.com Biotech Develops ADCs using cell-free protein synthesis for site-specific conjugation, including STRO-004 and dual-payload candidates.	Talk Mon Oct 12 12:30pm Exploring Next-Generation High DAR TOPO1i x DDRi Dual Payload ADCs to Improve Efficacy, Overcome Resistance & Enhance Safety Pre-conference: 10th ADCs in Combination Day Chair Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance Discovery Chemistry Talk Tue Oct 13 9:30am Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance Plenary Clinical developmentPreclinical development Talk Tue Oct 13 12:00pm Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers Preclinical Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Exelixis, Genentech, Callio Therapeutics +1 more ADC discovery chemistryManufacturing & supply chain Talk Wed Oct 14 2:30pm Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models Preclinical
Eli Lilly Indianapolis, IN
lilly.com Large pharma Global pharmaceutical company with an oncology pipeline that includes antibody-drug conjugates.	Chair Elevating Confident Characterization of Increasingly Complex Conjugates Pre-conference: 2nd Analytical & CQA Day Talk Mon Oct 12 10:00am Laying Out ADC CQAs & Understanding Regulatory Quality Perspectives as Complex Biologic & Small Molecule Therapies Pre-conference: 2nd Analytical & CQA Day Talk Mon Oct 12 10:30am Exploring Sofetabart Mipitecan Enhanced Anti-Tumor Activity in Combination with SoC Therapies in Ovarian Cancer Models to Support Clinical Development Pre-conference: 10th ADCs in Combination Day Workshop Thu Oct 15 9:00am Deep Diving Into CMC Best Practices to Ensure Stakeholder Alliance to Optimize ADC Production & Regulatory CMC Strategy Post-conference workshop for Manufacturing & Supply Chain · with Amgen